156 related articles for article (PubMed ID: 7779724)
1. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
De Placido S; Perrone F; Carlomagno C; Morabito A; Pagliarulo C; Lauria R; Marinelli A; De Laurentiis M; Varriale E; Petrella G
Br J Cancer; 1995 Jun; 71(6):1283-7. PubMed ID: 7779724
[TBL] [Abstract][Full Text] [Related]
2. Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA).
Boccardo F; Rubagotti A; Amoroso D; Perrotta A; Sismondi P; Farris A; Mesiti M; Gallo L; Pacini P; Villa E; Agostara B
Cancer Invest; 1997; 15(6):505-12. PubMed ID: 9412655
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
8. Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).
Chacon R; Romero Acuña L; Blajman C; Galvez C; Bruno M; Romero A; Chiessa G; Bader M; Schwan R; Albera C; Santarelli MT; Sousa Martínez F; Nadal J; Viniegra M
Br J Cancer; 1997; 76(4):545-50. PubMed ID: 9275035
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
[TBL] [Abstract][Full Text] [Related]
15. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
16. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
18. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
19. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
20. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]